Phase I study of daily oral AZD 2171, an inhibitor of the vascular endothelial growth factor receptor (VEGFR), in combination with carboplatin/paclitaxel in patients with advanced non-small cell lung cancer (NSCLC): A study of the NCICCTG. Conferences

Overview
Research
Additional Document Info
View All

authors

Laurie, SA
Arnold, Andrew
Gauthier, I
Ellis, Peter
Goss, G
Chen, E
Shepherd, F
Fisher, B
Robertson, J
Seymour, L

status

published

publication date

December 15, 2005

has subject area

1112 Oncology and Carcinogenesis (FoR)
Oncology & Carcinogenesis (Science Metrix)

published in

Clinical Cancer Research Journal

presented at event

AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics Conference